Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
16
CANF Quote, Financials, Valuation and Earnings
Last price:
$1.47
Seasonality move
:
-5.63%
Day range:
$1.42 - $1.50
52-week range:
$1.29 - $4.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.42x
P/B ratio:
3.64x
Volume:
208.1K
Avg. volume:
815.2K
1-year change:
-28.85%
Market cap:
$9M
Revenue:
$743K
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingCan Fite Biofarma has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Can Fite Biofarma has an estimated upside of 845.95% from its current price of $1.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.48.
Fair Value
-
According to the consensus of 0 analysts, Can Fite Biofarma has 845.95% upside to fair value with a price target of -- per share.
CANF vs. S&P 500
-
Over the past 5 trading days, Can Fite Biofarma has underperformed the S&P 500 by -4.43% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Can Fite Biofarma does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Can Fite Biofarma revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Can Fite Biofarma reported revenues of --.
Earnings Growth
-
Can Fite Biofarma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Can Fite Biofarma reported earnings per share of --.
Enterprise value:
4.3M
EV / Invested capital:
--
Price / LTM sales:
13.42x
EV / EBIT:
--
EV / Revenue:
11.19x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.96x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Income Statement | ||||||
| Revenue | $853K | $810K | $743K | $197K | $155K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$12.8M | -$10.1M | -$8.2M | -$3.1M | -$1.8M | |
| EBITDA | -$12.8M | -$10.1M | -$8.2M | -$3.1M | -$1.8M | |
| Diluted EPS | -$9.00 | -$3.00 | -$3.00 | -- | -$1.52 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.7M | $9.6M | $14.6M | $10.9M | $5.8M | |
| Total Assets | $12.8M | $9.7M | $14.7M | $11M | $5.9M | |
| Current Liabilities | $1.5M | $2.4M | $2.2M | $2.2M | $2M | |
| Total Liabilities | $3.6M | $5.7M | $4.9M | $4.2M | $3.4M | |
| Total Equity | $9.2M | $4M | $9.9M | $6.9M | $2.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.5M | -$4.3M | -$8.6M | -$1M | -$2.8M | |
| Cash From Investing | $21.5K | $20.1K | -$10.3K | $2.6K | -$530 | |
| Cash From Financing | $4.6M | $1.5M | $13.2M | $77.3K | $6M | |
| Free Cash Flow | -$5.5M | -$4.4M | -$8.6M | -$1M | -$2.8M | |
CANF
Sector
Market Cap
$9M
$43.9M
Price % of 52-Week High
31.56%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-28.85%
-29.11%
Beta (5-Year)
1.318
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.50
200-day SMA
Sell
Level
$2.37
Bollinger Bands (100)
Sell
Level
1.82 - 2.58
Chaikin Money Flow
Sell
Level
-357.8M
20-day SMA
Sell
Level
$1.73
Relative Strength Index (RSI14)
Sell
Level
35.58
ADX Line
Buy
Level
13.78
Williams %R
Buy
Level
-82.0755
50-day SMA
Sell
Level
$2.07
MACD (12, 26)
Sell
Level
-0.18
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
562.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-22.2999)
Sell
CA Score
(Annual)
Level (-4.0124)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (6.4532)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Stock Forecast FAQ
In the current month, CANF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CANF average analyst price target in the past 3 months is --.
-
Where Will Can Fite Biofarma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Can Fite Biofarma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Can Fite Biofarma?
Analysts are divided on their view about Can Fite Biofarma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Can Fite Biofarma is a Sell and believe this share price will drop from its current level to --.
-
What Is Can Fite Biofarma's Price Target?
The price target for Can Fite Biofarma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CANF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Can Fite Biofarma is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CANF?
You can purchase shares of Can Fite Biofarma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Can Fite Biofarma shares.
-
What Is The Can Fite Biofarma Share Price Today?
Can Fite Biofarma was last trading at $1.47 per share. This represents the most recent stock quote for Can Fite Biofarma. Yesterday, Can Fite Biofarma closed at $1.48 per share.
-
How To Buy Can Fite Biofarma Stock Online?
In order to purchase Can Fite Biofarma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
